Join to view full profile
110 Irving St Nw # 2a38Washington, DC 20010
Phone+1 202-877-2844
Dr. Shenoy is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Aarthi Shenoy is a Washington, DC-based oncologist with significant experience in Hematology and Medical Oncology. She completed her residency in Internal Medicine at the University of California (San Diego) Medical Center and her fellowship at the National Institutes of Health Clinical Center. Dr. Shenoy is a respected researcher with multiple publications on COVID-19 convalescent plasma therapy and the inflammatory responses after SARS-CoV-2 infection. She has been the lead investigator in various clinical trials, including trials related to SARS-CoV-2 and leukemia treatments. Dr. Shenoy's dedication to her field has been recognized with awards such as the CMS Meaningful Use Stage 1 Certification from ARIA Medical Oncology EMR, Varian Medical Systems in 2012 and 2014.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1997 - 2000
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
DC State Medical License 2008 - 2028
MD State Medical License 2010 - 2023
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification MEDSEEK Empower, SymphonyCare, LLC, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Combined elevated C-reactive protein and detectable plasma RNA has predictive value for hospitalization during an outpatient COVID-19 convalescent plasma clinical trial.Yuriko Fukuta, Atika Singh, Jiangda Ou, Leilani Montalvo, Clara Di Germanio
Journal of Clinical Virology Plus. 2026-11-01 - 9 citationsOutpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.Han-Sol Park, Anna Yin, Caelan Barranta, John S Lee, Christopher A Caputo
JCI Insight. 2024-03-14 - 5 citationsCOVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.Feben Habtehyimer, Xianming Zhu, Andrew D Redd, Kelly A Gebo, Alison G Abraham
Microbiology Spectrum. 2024-01-11
Press Mentions
MedStar Wants Recovered Coronavirus Patients to Donate PlasmaMay 15th, 2020
Charles and Mary Latham Fund Awards Three Research Grants to MedStar Health Research InstituteFebruary 9th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: